Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0149514 (bronchitis)
 6,902 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A newly developed macrolide clarithromycin (TE-031, A-56268), with antibacterial spectrum and antibacterial activity nearly equal to those of erythromycin (EM), shows beneficial characteristics such as a higher blood level, higher recovery rate in urine, and better penetration into each tissue than conventional macrolides (MLs). TE-031 has been studied in adults against various infections and proved to be useful. The present paper describes the results of a study in children to examine the usefulness of TE-031 granules and tablets with a potency of 50 mg. TE-031 granules were administered to 132 children with ages from 6 months to 13 years and 10 months. Excluded from the evaluation were 12 cases in which clinical effects were deemed unevaluable. The evaluable subjects consisted of 1 case with pharyngitis, 3 with tonsillitis, 9 with acute bronchitis, 19 with pneumonia, 19 with mycoplasmal pneumonia, 2 with scarlet fever, 20 with Campylobacter enteritis, 11 with impetigo, 2 with subcutaneous abscess, 18 with primary atypical pneumonia and 16 with acute enteritis of unidentified pathogens; a total of 120 subjects. An average daily dose of TE-031 was 25.9 mg/kg, divided into 3 doses except 1 case with 2 daily doses and lengths of the treatment averaged 7 days. TE-031 tablets each containing 50 mg potency, were administered to 49 subjects with ages from 3 year and a month to 14 years consisting of 8 cases with pharyngitis, 1 with tonsillitis, 1 with acute bronchitis, 4 with pneumonia, 14 with mycoplasmal pneumonia, 4 with scarlet fever, 5 with Campylobacter enteritis, 7 with impetigo, 1 with atypical pneumonia, 1 with Salmonella gastroenteritis and 3 with acute enteritis caused by unidentified pathogens, at an average daily dose of 13.5 mg/kg dived into 2-4 doses (2 doses/day for 12 cases, 3 doses for 32, 4 doses for 5) for 7 days on the average. In addition to examine the clinical and bacteriological effects of the 2 dosage forms of TE-031, minimum inhibitory concentrations (MICs) were determined for 9 antibiotics consisting of 5 MLs including TE-031, EM, josamycin (JM), midecamycin acetate (MDM acetate), and rokitamycin (RKM), 3 penicillins including ampicillin (ABPC), methicillin, cloxacillin and 1 cephem antibiotic, cefaclor (CCL), against 29 strains consisting of 12 strains of Staphylococcus aureus, 7 of Streptococcus pyogenes, 2 of Streptococcus pneumonia 2 of Haemophilus influenzae and 6 of Campylobacter jejuni, out of 71 strains of pathogens or possible pathogens that had been isolated from the cases given TE-031.
 ...
PMID:[Clinical study on clarithromycin granule and tablet in the field of pediatrics]. 252 56

We have studied clinically on 9,3"-diacetylmidecamycin (MOM), a new macrolide antibiotic derived from midecamycin. The following results were obtained. 1) Serum concentration. To the the same child weighing 15 kg and aged 4 years, the MOM dry syrup was administered orally at single doses of 150 mg (10 mg/kg) and 300 mg (20 mg/kg) and then the MDM fine granules at a single dose of 300 mg (20 mg/kg). At dosages of 10 mg/kg and 20 mg/kg of MOM dry syrup and 20 mg/kg of MDM fine granules, the serum concentrations were 0.5 microgram/ml, 0.8 microgram/ml and not detectable (N.D.) respectively, at 45 minutes after administration; 0.4, 0.6 and N.D. at 1 hour; 0.12; 0.2 and N.D, at 2 hours; N.D., less than 0.1, N.D. at 4 hours; N.D. in all the cases at 6 hours. 2) Clinical results. MOM dry syrup was administered to 25 children. The efficacy rate was 68.75% except for 1 dropout case and the elimination rate of 11 isolated strains of group A Streptococcus was 9.09% in 16 cases of scarlet fever and 1 of acute pharyngitis caused by group A Streptococcus. With 6 cases of pertussis were eradicated. The clinical response to 1 with acute bronchitis and 1 with Mycoplasma pneumonia were good and poor respectively. 3) Side effect. No clinical side effect and abnormal laboratory findings were observed in any of the 25 cases administered MOM dry syrup.
 ...
PMID:[Clinical study on 9,3"-diacetylmidecamycin in the field of pediatrics (author's transl)]. 698 Feb 95